Search tips
Search criteria 


Logo of plospathPLoS PathogensSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)View this Article
PLoS Pathog. 2010 July; 6(7): e1001018.
Published online 2010 July 29. doi:  10.1371/journal.ppat.1001018
PMCID: PMC2912399

Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity

Michael Gale, Jr, Editor


Hepatitis C Virus (HCV) is a major public health concern, with no effective vaccines currently available and 3% of the world's population being infected. Despite the existence of both B- and T-cell immunity in HCV-infected patients, chronic viral infection and HCV-related malignancies progress. Here we report the identification of a novel HCV TCR from an HLA-A2-restricted, HCV NS3:1073–1081-reactive CTL clone isolated from a patient with chronic HCV infection. We characterized this HCV TCR by expressing it in human T cells and analyzed the function of the resulting HCV TCR-transduced cells. Our results indicate that both the HCV TCR-transduced CD4+ and CD8+ T cells recognized the HCV NS3:1073–1081 peptide-loaded targets and HCV+ hepatocellular carcinoma cells (HCC) in a polyfunctional manner with cytokine (IFN-γ, IL-2, and TNF-α) production as well as cytotoxicity. Tumor cell recognition by HCV TCR transduced CD8 Jurkat cells and CD4+ PBL-derived T cells indicated this TCR was CD8-independent, a property consistent with other high affinity TCRs. HCV TCR-transduced T cells may be promising for the treatment of patients with chronic HCV infections.

Author Summary

Hepatitis C Virus (HCV) is a major public health concern with a large number of individuals infected (3% world wide). Currently, there is no effective vaccine available to prevent HCV infection and the treatment is effective in less than half of all patients. Therefore, many patients have long term infections that lead to severe liver damage or liver cancer. It has been shown that some HCV infected patients can eliminate the virus and the host immune system is involved. The problem is most people do not have the capacity to fight their HCV infection. We have developed a gene therapy based approach where a patient's own immune cells can be made to recognize cells expressing HCV genes. This can be accomplished regardless of his or her natural capacity to fight their HCV infection. This manuscript describes how normal immune cells can be genetically altered to recognize cells expressing HCV proteins and characterizes their reactivity and sensitivity to antigen stimulation.


Hepatitis C Virus (HCV) infection is a major public health concern with approximately 3% of the world's population being infected [1]. Unfortunately, 70–80% of infected individuals are unable to clear the virus, resulting in a chronic infection with the potential for developing severe liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) [2], [3]. These liver diseases are the major indication for liver transplantation in the US and Europe [4], [5]. The combination therapy of interferon-α and ribavirin is used to treat HCV infections with limited success [6]. The development of preventative and therapeutic vaccines has been hindered by a lack of relevant animal models to study HCV viral replication and disease progression in vivo.

Both cellular and humoral immunity exists against HCV proteins in HCV-infected individuals [7]. However, not all HCV-infected patients can mount an effective anti-HCV immune response leading to the reduction of the viral load [8], [9]. There is evidence that demonstrates that the HCV genome mutates rapidly suggesting that mutations in T-cell and B-cell epitopes lead to immune escape variants which may be the main reason for HCV persistence in chronically infected patients [10][12]. Therefore, until better immune-based strategies are developed, immune therapy will have limited benefit for HCV-infected patients.

An approach has been described in which retroviral vectors encoding T-cell receptor (TCR) genes are used to redirect the specificity of normal peripheral blood lymphocyte (PBL)-derived T cells to recognize the melanoma associated antigen, MART-1 [13], [14]. Subsequently, this approach has been extended to other tumor antigens and viruses [15][28]. In fact, three phase I/II clinical trials using this approach to treat melanoma have been reported [29][31]. In two of these studies, no serious adverse events were observed and a few objective clinical responses were reported [29], [30]. However, the third study reported an increase in the frequency of clinical responses but a few patients experienced adverse events [31]. With TCR gene transfer becoming a reality for cancer patients, it opens the possibility for engineering a patient's own T cells to recognize their HCV virus-infected cells, regardless of their immune status.

It has also been well known that the HCV genome contains several regions and it is genetically unstable and mutates readily. The high variation of HCV is used to produce escape mutants that can sneak past the immune response of the host. The variants also play a significant role in the progression of virus infection due to resistance to immunotherapy. We have previously identified HCV NS3:1406–1415 reactive T cells that express high-affinity TCRs [24], [32]. In the current study, we cloned novel HCV TCR genes from an HLA-A2-restricted, HCV NS3:1073–1081-reactive, T-cell clone isolated from a patient with chronic HCV infection. This is an important epitope since it is frequently the immunodominant epitope targeted by anti-HCV CTL in HCV infected patients [33]. It also shares sequence homology with a peptide from the influenza A virus and CTL have been shown to crossreact with both peptides [34]. And finally, it is often mutated in HCV immune escape variants making it likely to be an important target in the anti-HCV immune response [35]. For the first time, we demonstrate that a recombinant retroviral vector encoding the HCV NS3:1073–1081 TCR could efficiently transduced both CD4+ and CD8+ T cells. Functional analysis demonstrates that the HCV TCR-transduced both CD4+ and CD8+ T cells produce interferon-γ, TNF-α, and to a lesser extent, IL-2 when stimulated with the peptide-loaded targets or HCV+ hepatoma cells. Our results indicate that an HCV TCR can engineer antigen reactive CD4+ and CD8+ T cells, raising the possibility that we can provide any HCV patient with a source of autologous HCV-reactive T effector and helper cells which have been implicated in eradicating HCV infections.


Identification of the TCR Genes Used by an HCV Reactive T Cell Clone

An HCV NS3:1073–1081-reactive CTL clone was isolated from the blood of a patient with a chronic HCV infection by limiting dilution cloning. The T cell clone was analyzed for antigen recognition in cytokine release assays. As shown in Figure 1, the T cell clone secreted significant amounts of interferon-γ when stimulated with T2 cells loaded with the HCV NS3:1073–1081 peptide but not the control CMVpp65 or HCV NS3:1406–1415 peptides. These results indicate that the T cells isolated from the patient with a chronic HCV infection were reactive with the HCV NS3:1073–1081 antigen.

Figure 1
Antigen recognition by HCV T-cell clone 1073.

The HCV NS3:1073–1081 TCR α and β chains from the HCV NS3:1073–1081-reactive, T cell clone were identified as described [36]. The germline V genes, J regions, and the unique CDR3 region sequences for each TCR chain are shown in Figure 2. DNA sequence analysis of random 5′ RACE TCR α chain cDNA clones revealed the HCV NS3:1073–1081 T cell clone expressed a single TCR α chain consisting of AV20s1/AJ10/AC. This TCR α chain was in-frame and contained all of the landmarks consistent with a functional TCR α chain. The TCR β chain was identified by RT-PCR using a panel of TCR BV subfamily specific primers as described [37]. The only primer that amplified a fragment of the predicted size was the BV13 primer suggesting that the TCR expressed by the HCV NS3:1073–1081 reactive T cell clone used member of the BV13 subfamily (data not shown). DNA sequence analysis of that PCR fragment revealed that the TCR β chain consisted of BV13s6/BJ2s1/BJ2s7/BC2. Like the TCR α chain, the DNA sequence of the TCR β chain indicated it was in-frame and contained all of the features consistent with a functional TCR β chain. The identification of the TCR β chain being BV13 was confirmed by immunofluorescence staining with an anti-Vβ13s6 mAb (data not shown). Thus, the HCV NS3:1073–1081 T cell clone expresses an AV20s1/BV13s6 TCR.

Figure 2
Junctional sequences of the TCR α chain and the TCR β chain identified from HCV NS3:1073–1081 clone.

Construction of an HLA-A2+ HCC Cell Line Expressing the HCV NS3:1073–1081 Epitope

The critical feature for a TCR gene-modified T cell is its ability to recognize endogenous antigen on the target-cell surface. However, human liver or HCC cells infected with HCV were not available for our experiments. Therefore, we established an HCV expressing HCC cell line to test the ability of our TCR-transduced T cells to recognize HCV+ liver tumor cells. An HCV expression construct was prepared by fusing the HCV NS3:1073–1081 minigene to the EGFP gene which was used as a marker to monitor the level of antigen expression by the HCC cells. The HCV/EGFP fusion construct was inserted into the retroviral vector pMFG (Figure 3A) which was used to transduce the HLA-A2+ hepatocellular carcinoma cell line, HepG2 (HLA-A2 expression is shown in Figure S1). HCV minigene-positive cells were defined by their EGFP expression as measured by flow cytometry (Figure 3B) and EGFP expressing cells were sorted by FACS for high and homogeneous antigen expression. The HCV+ HCC cells were then used as stimulators in cytokine release assays to evaluate the function of HCV TCR transduced T cells.

Figure 3
HCV NS3:1073–1081 expression in the hepatocellular carcinoma cell line HepG2.

HCV NS3:1073–1081 Antigen Recognition by HCV TCR-Transduced Jurkat Cells

We have generated the recombinant retroviral construct containing the TCR α and β chains of the HCV NS3:1073–1081 reactive T cell clone (Figure 4). To verify the expression and function of this cloned TCR, we used this retroviral vector to transduce Jurkat 76 cells. Jurkat 76 cells are a TCR α and β derivative of the CD8 human T cell lymphoma Jurkat cell line. Since Jurkat 76 cells are TCR negative, any introduced TCR would not have to compete with the endogenous TCR and its expression can be monitored by staining with anti-CD3 mAb. Furthermore, Jurkat 76 cells expressing a cloned TCR secrete IL-2 upon antigen stimulation in an antigen-specific fashion. Therefore, Jurkat 76 cells are an excellent model to evaluate the expression and function of any cloned TCR. As shown in Figure 5A, Jurkat 76 cells expressing the HCV NS3:1073–1081 TCR stained with anti-Vβ13.6 and anti-CD3 mAb's indicating the TCR could assemble on the surface of the Jurkat 76 cells. When stimulated with antigen, these HCV TCR transduced Jurkat 76 cells secreted significant IL-2 in response to T2 cells loaded with the HCV NS3:1073–1081 peptide but not T2 cells alone or T2 cells loaded with the CMV pp65:495–503 peptide (Figure 5B). The HCV TCR transduced Jurkat 76 cells also recognized HepG2 cells loaded with the HCV NS3:1073–1081 peptide or transfected to express the HCV NS3:1073–1081 epitope. It should be noted that despite the mock transfectants having higher expression of EGFP (Figure 3B), they were not recognized by the Jurkat cells expressing the HCV TCR. More importantly, recognition of HCV+ HepG2 cells by CD8 Jurkat cells indicates our HCV TCR transfers CD8 independent tumor cell recognition to alternate effectors. These results indicate the HCV TCR is functional and has high affinity for antigen.

Figure 4
Structure of retroviral vectors used for TCR gene transfer and TCR expression on transduced cells.
Figure 5
Expression and Function of the HCV TCR in Jurkat 76 cells.

Recognition of HCV+ Hepatocellular Carcinoma Cells by the HCV TCR-Transduced T Cells

Although Jurkat 76 cells are a good model cell line for verifying the function of a cloned TCR, they can't be used in preclinical animal studies or clinical trials to control HCV infections or the growth of HCV+ HCC cells. Therefore, it is critical to evaluate the function of normal PBL-derived T cells expressing our HCV TCR, particularly with regards to their ability to recognize a physiologically relevant target such as hepatocellular carcinoma cells. To accomplish this goal, we generated populations of HCV TCR transduced PBL-derived T cells from a total of seven normal healthy donors. The level of expression and the percent HCV TCR transduced T cells was measured by anti-Vβ13.6 mAb staining. The results from a typical HCV TCR transduced T cell culture is shown in Figure 6A. Compared to the isotype control, mock transduced T cells contained 1.1% Vβ13.6 staining cells. This represents the frequency of Vβ13.6 staining cells present in normal PBL. The HCV TCR transduced T cell cultures contain 36% Vβ13.6 staining cells with the level of TCR expression being variable as expected by a TCR-transduced T cell population. These results indicate that our HCV TCR can be efficiently expressed by PBL-derived T cells from normal donors. However, despite having anywhere from 20%–40% Vβ13 expressing T cells in the HCV TCR transduced T cell cultures, only about 0.25% of the CD4+ and CD8+ T cells bind HCV 1073 peptide loaded pentamers (Figure S2). We and others have found that tetramer binding does not always correlate with TCR expression and function so this result was not surprising [38][40].

Figure 6
Antigen recognition by HCV TCR 1073-transduced PBLs.

PBL-derived T cells from the normal donors were transduced with our HCV TCR and assessed for their ability to recognize antigen. Using a combination of cytokine release and intracellular cytokine staining, we evaluated the antigen reactivity of each of the HCV TCR transduced T cell cultures. All of the bulk T cell cultures produced significant amounts of interferon-γ when stimulated with T2 cells loaded with the HCV NS3:1073–1081 peptide but not T2 cells alone or T2 cells loaded with the control CMV pp65:495–503 peptide (Figure 6B, Figure 7, and Figure S3). These HCV TCR transduced T cells did produce TNF-α and IL-2 upon stimulation with peptide loaded T2 cells (Figure 7 and Figure S3). The HCV TCR transduced bulk T cells also efficiently recognized HepG2 cells (which naturally express HLA-A2; Figure S1) loaded with HCV NS3:1073–1081 peptide or transfected to express the HCV NS3:1073–1081 epitope (Figure 6 and Figure S3). It should be noted that despite the mock transfectants having higher expression of EGFP (Figure 3B), they were not recognized by the normal PBL-derived T cells expressing the HCV TCR. Moreover, TCR-transduced PBL demonstrated cytotoxicity as shown by the production of CD107a (Figure 8). Therefore, our HCV TCR efficiently engineers normal PBL-derived T cells to recognize HCV peptide loaded targets with a polyfunctional response (production of IFN-γ, IL-2, TNF-α and CD107a).

Figure 7
Intracellular cytokine staining of HCV TCR transduced T cells.
Figure 8
CD107a staining of HCV TCR 1073-transduced T cells.

Recognition of peptide loaded targets by HCV TCR-transduced T cells confirms the reactivity of our HCV TCR in normal PBL-derived T cells. However, it is more important to verify the recognition of antigen presented by HCV+ cells such as HCC cells. The recognition of HCV+ HepG2 cells by the HCV TCR transduced Jurkat 76 cells indicated that our HCV TCR transfers CD8-independent tumor cell recognition to alternate effectors (Figure 5B). We have previously reported that CD8 independent TCR's are capable of generating MHC class I restricted CD4+ T cells making it possible to provide patients with a novel source of T cell help [41], [42]. To determine if our HCV TCR can generate MHC class I restricted CD8+ effector and CD4+ helper T cells, we transduced PBLs derived T cells from three healthy donors and purified the CD4+ and CD8+ T cells to greater than 99% purity using immunomagnetic beads to measure cytokine production by ELISA (Figure 6 and Figure S3) or analyzed each subset for intracellular cytokine production or CD107a expression (Figure 7 and Figure 8). CD4+ and CD8+ T cells, transduced to express our HCV TCR, produced significant amounts of interferon-γ, TNF-a, IL-2, and CD107a when stimulated with HCV peptide loaded T2 cells or HepG2 cells but not controls. Importantly, the HCV TCR-transduced CD4+ T cells secreted significant amounts of cytokine when stimulated with HCV+ tumor cells. These results indicate that our HCV TCR can engineer both CD8+ T cells and CD4+ T cells to recognize HCV+ cells. Also, our ability to generate MHC class I restricted CD4+ T cells raises the possibility that we can provide any HCV patient with a source of autologous HCV-reactive T helper cells which has been implicated in eradicating HCV infections [43].

Relative Functional Avidity of HCV TCR-Transduced T Cells

It has been shown that there is a correlation between the functional avidity of a T cell and its ability to recognize tumor cells or virus-infected cells [43][47]. Furthermore, T cells expressing a high affinity TCR have been shown to be exquisitely sensitive to low levels of antigen [48]. T cells with identical specificities, but different functional avidities, influence each other during activation and homeostatic proliferation [49]. T cells exhibiting increased sensitivity to stimulation, or a lower threshold, are said to have a relatively high functional avidity [44][47]. T-cell responsiveness to peptide is commonly used as a measure of T cell avidity as it provides a measure of the stimulation threshold required to activate T cell effector functions. Relative avidities were evaluated by measuring T-cell interferon-γ production. To test the avidity of the HCV TCR-transduced T cells, we loaded different peptide concentrations on T2 or HepG2 cells and incubated with HCV TCR transduced T cells. The ability of the transduced T cells to produce interferon-γ was measured under conditions of increasing concentrations of peptide stimulation. As shown in Figure 9, the two representative HCV TCR transduced T cell cultures (Donors 4 and 5) had high avidity for antigen since they secreted significant amounts of interferon-γ when stimulated T2 cells loaded with 5 nM or less of peptide. Similar results were found with three other HCV TCR transduced T cells cultures (Donors 1–3) with the functional avidity of the HCV TCR transduced T cells being approximately half a log lower than the parent T cell clone (<1.0 vs <0.5 nM) (Figure S4).

Figure 9
Functional avidity of HCV TCR 1073-transduced T cells.

In contrast, Peptide loaded HepG2 cells were not recognized as well as the T2 cells since it required between 50–500 nM peptide to stimulate the HCV TCR transduced T cells. This was not surprising since our HepG2 cells but not our T2 cells have their MHC class I molecules loaded with peptides requiring peptide exchange on the HepG2 cells for T cell recognition to occur. In fact, the HCV TCR transduced T cells did not recognize the HepG2 cells loaded with 5 µM peptide as well as the HepG2 cells expressing the HCV 1073 minigene (576/345 pg/ml vs 717/418 pg/ml respectively for donors 1 and 2) further supporting the notion that exogenous peptide loading was less efficient than endogenous peptide loading. Compared to other published studies, our functional avidity measurements using peptide loaded T2 cells indicate our HCV TCR transduced T cells have relatively high avidity for antigen.


The relationship between T cell avidity and the clearance of viral infections and tumor cells has been well documented [44], [45]. Many studies have been directed at elucidating the relationship between T-cell activity and TCR affinity, dissociation rate, and CD8+ dependence. CD8+ played an essential role in T-cell recognition of low-affinity T-cell reactions [48]. However, we speculated that any TCR that can bind peptide/MHC complexes without CD8 would have higher relative affinity than a TCR that requires CD8+ for binding. To date, only a limited number of CD8-independent TCRs have been cloned and characterized [50]. The novel HCV TCR described herein exhibits CD8-independent target cell-recognition since the HCV TCR-transduced CD4+ T cells could secret interferon-γ and IL-2 when stimulated with peptide-loaded targets or HCV+ HCC cells (Figure 6B and Figure S3). Based on this study, we conclude that the affinity of this HCV TCR is higher than other TCRs that require the CD8 coreceptor for target-cell recognition, These results indicate that T cells isolated from patients with chronic HCV infection can have high affinity TCRs and these TCRs may be important for developing novel TCR-based gene therapy studies. Thus, we have identified another high affinity TCR that could be used to engineer normal PBL-derived T cells for clinical application.

CD4+ T cells are thought to contribute to anti-viral immune responses by secreting cytokines, thereby providing help to CD8+ T cells [51], [52]. Antigens are taken up by antigen presenting cells which may activate CD4+ T cells to secrete either Th1 or Th2 cytokines. By producing Th1-cytokines like interferon-γ and IL-2 CD4+ T cells contribute to anti-viral immune responses providing help to CD8+ T and B cells. Furthermore, CD4+ T cell lines and clones can display direct cytotoxic effector function [51], [52]. The identified HCV TCR has been successfully transduced into CD4+ T cells and these TCR-transduced CD4+ T cells may not only provide help to CD8+ T cells, but also directly act on the HCV+ target cells such as HCV-infected cells and HCV+ HCC cells. This is especially important for clearing HCV infection because one of the fundamental problems typical of chronic HCV infection is a weak or absent HCV- specific CD4+ T-cell response [43], [53].

The instability of the HCV genome makes the identification of this high affinity HCV NS3:1073–1081 TCR particularly important. We and others have previously shown that T cells can express two functional TCRs capable of recognizing both target antigens [54][56]. Therefore, when combined with our previously identified HCV NS3:1406–1415 TCR, T cells expressing both TCRs might be effective against HCV immune escape variants for treatment of HCV-associated diseases. Adoptive transfer of HCV TCR-transduced T cells may show promise as a new treatment for patients with chronic HCV infection or HCV-related malignancies, particularly in light of the recent demonstration that HCC express HCV antigens [57].

Materials and Methods

Cell Lines, Media, and Reagents

T2 and HepG2 cells were obtained from the American Type Culture Collection (Rockford, MD). The TCR-negative Jurkat 76 cell line has been described elsewhere [58]. Unless otherwise indicates, All medium components were obtained from Mediatech (Herndon, VA) unless otherwise noted. Jurkat 76 and T2 cell lines were maintained in complete medium consisting of RPMI 1640 medium supplemented with 10% fetal bovine serum (Tissue Culture Biologicals, CA) 100 U/mL penicillin, 100 µg/mL streptomycin. Plat-A cells [59], [60] and HepG2 cells were maintained in Eagle's medium supplemented as described above. TCR-transduced Jurkat 76 cells were maintained in RPMI medium as described above supplemented with 2 mg/mL G418.

To engineer tumor cell lines to express HCV sequences, we first inserted synthetic oligonucleotides encoding the HCV NS3:1073–1031 epitope into the retroviral vector, pMFG-EGFP. Briefly, oligonucleotides encoding the HCV NS3:1073–1031 epitope and containing mutated Nco I restriction sites (forward: 5′-catgTGCATCAATGGGGTATGCTGGACTGTCgctgcttatgg-3′; reverse 5′- ccataagcagcGACAGTCCAGCATACCCCATTGATGCAcatg-3′) were synthesized and annealed. The underlined base pairs indicate the overhang for the ligation of the double stranded oligonucleotides into the pMFG-EGFP vector using a shotgun ligation strategy as described [41]. The recombinant vector was transiently transfected into Plat-A packaging cells and the retrovirus containing supernatant was collected for transduction of HepG2 cells. The expression of the HCV NS3:1073–1081 minigine in the transduced HepG2 cells was confirmed based on the EGFP expression as measured by flow cytometry. The EGFP positive cells were sorted for high and uniform expression and the resulting HCV+ HCC cell line was established.

T Cells

All T cells were maintained in AIM V medium (Invitrogen, GIBCO) supplemented with 5% heat-inactivated pooled human AB serum (Valley Biomedical, Inc), 100 U/mL penicillin, 100 µg/mL streptomycin and 300 IU/mL recombinant human IL-2 (rhIL-2; Novartis Pharmaceuticals Corporation, East Hanover, NJ) at 37°C in a humidified 5% CO2 incubator. The isolation and characterization of HCV-reactive T-cell clones has been previously described [32]. The HCV NS3:1073–1081-reactive CD8+ T-cell clone used in this study was isolated from a patient with a chronic HCV infection.. All PBMC used in this study came from apheresis products purchased from (Research Blood Components, L.L.C., MA). Normal PBL-derived T cells were isolated from the PBMC cells of three independent normal healthy donors using Ficoll-Hypaque density gradient centrifugation. The HCV T cell clone and the TCR-transduced T cells were expanded using 30 ng/mL anti-CD3 monoclonal antibody (Ortho Biotech, Raritan, NJ) and 300 IU/mL rhIL-2 in the presence of irradiated pooled allogeneic peripheral blood mononuclear cells as feeders as previously described [61].


HCV NS3:1073–1081 (CINGVCWTV), HCV NS3:1406–1415 (KLVALGINAV), CMV pp65:495–503 (NLVPMVATV) were obtained from Synthetic Biomolecules (San Diego, CA). T2 or HepG2 cells were loaded with each peptide by incubating 1×106 cells/ml in complete medium containing 5 µg/ml (unless otherwise noted) of peptide at 37°c for 2 hours. Peptide-loaded cells were washed with fresh complete medium before coculture with responders.

TCR α and β Chain Identification

The TCR α chain from the HCV NS3-1073–1081-reactive T-cell clone was identified by 5′ RACE as previously described [37], [60]. Briefly, total RNA was isolated from 2.5×106 cells using TRIzol (Invitrogen), first-strand cDNA was synthesized, and the TCR cDNAs were amplified using the SMART RACE cDNA Amplification kit (Clontech Laboratories, Inc, Mountain View, CA). Fragments containing random TCR α chains were amplified using the Advantage 2 PCR Enzyme system (Clontech Laboratories, Inc) using the universal primer A mix and a TCR α constant region (AC) specific reverse primer. The random PCR products were ligated into TA PCR2.1-Topo cloning vector, and transformed into Escherichia coli TOP 10 competent cells (Invitrogen). Bacterial clones were screened for the presence of TCR α chain cDNA by PCR and random 5′ RACE clones were sequenced using fluorescent dye labeled ddNTPs (Applied Biosystems Inc, Foster City, CA). DNA sequence analysis revealed a single productively rearranged TCR α chain which used the AV20s1. The full-length α chain was amplified from cDNA using an AV20s1 forward (5-AAGTCGACGTTTGCACCTAGAATATGAGGCAAGTGGCG-3) and an AC reverse (5-AAGTCGACTCAGCTGGACCACAGCCGCAG-3) primer containing Sal I restriction sites for subsequent subcloning. The PCR product was ligated into the pCR 2.1 TA cloning vector (Invitrogen), and transformed into Escherichia coli TOP 10 competent cells (Invitrogen). Bacterial clones were screened for the presence of the α chain cDNA via PCR and were sequenced to ensure that no errors had occurred during PCR amplification.

The TCR β chain from the HCV-reactive T-cell clone was identified via RT-PCR using a panel of TCR β chain V region (BV) subfamily specific primers as previously described [37]. Briefly, total RNA was isolated and first strand cDNA was prepared from 2.5×106 T cells using the procedure as described above for the α chain identification. A single band was amplified using the BV13 subfamily specific primer and the TCR β chain was identified as BV13s6 based on known TCR BV genomic DNA sequences. The full-length β chain was amplified from cDNA using a BV13s6 forward (5′-CTCGAGGCACCTGCCATGAGCATCAGCCTC-3′) and a BC2 reverse (5′-AACTCGAGCTAGCCTCTGGAATCCTTTCTCTTGACCAT-3′) primer that each contained Xho I restriction sites for subsequent subcloning. The PCR fragment was ligated into the pCR 2.1 TA cloning vector, and transformed into Escherichia coli TOP 10 competent cells. Bacterial clones were screened for the presence of the β chain gene, and recombinant clones were sequenced to ensure that no errors had occurred during PCR amplification.

Retroviral Vector Construction

The SAMEN CMV/SRα retroviral vector has been previously described [14] and was used as the backbone for all retroviral constructs. The TCR α and β chains were linked by a 2A self cleavage peptide. The HCV TCR α chain, 2A linker and β chain fusion gene fragment was inserted into the Xho I and Sal I restriction sites of the retrovirus vector. The configuration of the retroviral vector used in this study is shown in Figure 4.

Retroviral Transduction

Retroviral supernatants were prepared using a transient transfection protocol as described [41]. Briefly, 5×106 Plat-A cells were plated in 10 cm poly-D-Lysine coated plates in 10 ml DMEM containing 10% FBS without antibiotics at sufficient density to provide 60% to 70% confluence after 24 hr. Cells were transiently cotransfected with 9 µg of retroviral vector DNA and 4.5 µg of plasmid DNA containing the vesicular stomatitis virus envelope gene using Lipofectamine 2000 (Invitrogen). Transfection medium was replaced with 10 ml complete medium after 6 h incubation, and retroviral supernatants were collected after 48 hr.

Jurkat 76 were transduced by spinoculation as described [14]. Briefly, Jurkat 76 cells were resuspended at a concentration of 2×106/ml in retroviral supernatant containing 8 µg/mL polybrene. 1 ml of cells was added to each well of a 24-well flat-bottom tissue culture plate then spun for 90 min at 1000×g at 32°C. After centrifugation, the cells were resuspended in their wells, incubated for 4 hr at 37°C, and 1 mL fresh complete medium was added to each well. This spinoculation procedure was repeated the next day using fresh retroviral supernatant. After 24 hr, the transduced cells were resuspended at 5×105/ml in culture medium and transduced cells were selected by the addition of 2 mg/mL of G418.

T cells were transduced by spinoculation as described [14]. Briefly, retrovirus was first loaded onto RetroNectin-coated 24-well flat-bottom non-treated tissue culture plates by adding 1 mL of fresh retroviral supernatant per well and the plates were spun for 2 hr at 2,000×g at 32°C. T cells derived from healthy donors were activated using 50 ng/mL anti-CD3 monoclonal antibody and 300 IU/mL rhIL-2. The activated T cells were resuspended at 1×106 cells/mL with culture medium supplemented with 300 IU/mL of rhIL2. The T cells were then gently added to the plates and mixed with the viral supernatnant. The plates were continuously centrifuged at 1,000×g for 10 min at 32°C. After 24 hours, the transduced T cells were selected by adding 1 mg/mL of G418. The CD4+ T cells were sorted from the TCR-transduced T cells by positive selection with magnetic beads. The purity of separated CD4+ and CD8+ cells was confirmed by FACS analysis.

Immunofluorescence Staining

All T cell and tumor cell lines were stained for immunofluorescence with fluorochrome conjugated anti-CD3 (APC), Vβ13.6 (FITC), anti-CD4 (APC), anti-CD8 (FITC), anti-CD107a, (PE) and anti-HLA-A2 (PE) purchased from BD Biosciences, San Diego, CA. PE conjugated HCV NS3:1073–1081 or HCV Core:132–140 peptide loaded HLA-A2 pentamers were purchased from Proimmune Ltd., Oxford, United Kingdom. In all experiments, 106 live cells were stained for 30 minutes on ice with individual monoclonal antibodies or pentamers. Cells were washed and stained with a second reagent or analyzed immediately on an Accuri C6 or BD FACSCalibur flow cytometer. The log fluorescence of a minimum of 106 cells was analyzed for each sample.

Cytokine Release Assays

Antigen reactivity by the HCV-reactive T cell clones and HCV TCR transduced cells was measured in cytokine release assays as described [13]. Briefly, 1×105 responder and stimulator cells were cocultured in a 1[ratio]1 ratio in 96-well U-bottom tissue culture plates in 200 µL complete medium. For the Jurkat 76 experiments, 10 ng/mL of PMA (Sigma-Aldrich, St. Louis, MO) was added to each well. As a positive control for Jurkat stimulation, maximal cytokine release was obtained by the addition of 1 µg/mL ionomycin (Sigma-Aldrich). Cocultures were incubated at 37°C for 20 hours, and then supernatants were harvested. The amount of cytokine released was measured via ELISA using monoclonal antibodies to interferon-γ (Pierce, Rockford, IL) or IL-2 (R&D Systems, Minneapolis, MN).

Intracellular Cytokine Staining

Multiparameter flow cytometry was performed using a BD FACSCanto II instrument (BD Biosciences, San Jose, CA) and analyzed using FACSDiva software (BD). Antibodies for cell surface CD3, CD4 and CD8 and for intracellular IFN-γ, TNF-α, and IL-2 were purchased from BD or eBioscience (San Diego, CA). Transduced T cell cultures were stimulated for 6 hours at 37°C in the presence of brefeldin A (Sigma-Aldrich) with equal numbers of T2 cells that had previously been loaded with the TCR-specific antigen (HCV-1073 peptide, 1 µg/ml) or with another HCV-derived A2-restricted control peptide (HCV-132, 1 µg/ml). After stimulation cells were stained for surface antigens, fixed for 30 minutes at 4°C in 100µl Fix and Perm Medium A (Caltag, Burlingame, CA), permeabilized using 100µl Fix and Perm Medium B (Caltag) and incubated with anti-cytokine antibodies for 1 hour at 4°C. Cell suspensions were then washed in PBS-BSA-Azide and fixed in 200 µl 1% PFA and acquired after 1 hour.

CD107a Expression Assay

CD107a expression was used as a surrogate marker to assess the cytolytic ability of HCV 1073 TCR transduced T cells. HCV 1073 TCR transduced T were cocultured with a panel of stimulators using methods similar our cytokine release assays described above. Stimulators included T2 cells loaded with the HCV NS3:1073–1081 or CMV pp65;495–503 and tumor targets (HepG2 and HepG2 expressing the HCV 1073 minigene). Briefly, 1×105 responder and stimulator cells were cocultured in a 1[ratio]1 ratio in 96-well U-bottom tissue culture plates in 200 µL complete medium. Cocultures were incubated at 37°C for 20 hours, and then cells were harvested and washed. The cells were stained with anti-CD3 mAb, anti-CD8 mAb and anti-CD107a mAb (BD Pharmingen, San Diego, CA) and were analyzed by flow cytometer. Each histogram represents the log fluorescence of 104 live T cells (gated using CD3 staining).

Supporting Information

Figure S1

HLA-A2 expression on human HCC lines. HepG2 HCC cells were used throughout this study as stimulator cells for the HCV TCR transduced T cells. To confirm their HLA-A2 expression levels, HepG2 cells were stained with PE conjugated anti-HLA-A2 mAb (solid curve) or and isotype control mAb (open curve) and the amount of fluorescence staining was quantified by flow cytometry. As staining controls, the HLA-A2 negative HCC cell line Huh-7 and an HLA-A2 transfectant was stained. Each histogram represents the log fluorescence of 104 live cells.

(0.08 MB TIF)

Figure S2

Pentamer staining of HCV TCR transduced T cells. HCV TCR transduced normal PBL-derived T cells were stained HCV peptide loaded pentamers. Two representative TCR transduced T cell cultures (Donors 4 and 5) and a normal donor untransduced cells (Donor 5) were stained with anti-CD4 mAb, anti-CD8 mAb, and HLA-A2 pentamers loaded with the HCV NS3:1073–1081 peptide. The percent pentamer positive CD8+ T cells (upper row) and CD4+ T cells (lower row) is shown in each histogram. Each histogram represents the log fluorescence of 104 live cells.

(0.23 MB TIF)

Figure S3

Cytokine production by HCV TCR 1073-transduced T cells. PBMC from two normal donors (donors 4 and 5) were transduced to express the HCV TCR 1073 and were assessed for cytokine secretion. T2 cells were pulsed for 2 hr with 5 µg/ml of the HCV NS3 1073–1081 peptide or the CMV pp65 control peptide. Peptide-pulsed T2 cells, HepG2 cells and HCV+ HepG2 cells were cocultured for 20 hr in microwells with the HCV TCR 1073 T cells. The production of IFN-γ and IL-2 were measured by ELISA.

(0.06 MB TIF)

Figure S4

Relative avidity of HCV TCR 1073-transduced T cells. The functional avidity of HCV TCR transduced PBL-derived normal T cells was compared to the parent HCV NS3:1073:1081 T cell clone using interferon-γ release assays. T2 cells were loaded for 2 hr with varied concentrations of HCV NS3 1073–1081 peptide (0.01–1000 nM). These peptide-loaded T2 cells were cocultured for 20 hr in microwells with three different HCV TCR transduced T cell cultures or the parent HCV 1073-reactive T cell clone. The amount of interferon-γ produced was measured by ELISA.

(0.06 MB TIF)


The authors wish to thank Ms. Mingli Li for technical assistance. The authors are grateful to the MUSC Center for Cellular Therapy for their invaluable support. Plat-A cells were kindly provided by Dr. Toshio Kitamura.


The authors have declared that no competing interests exist.

This work was supported by start up funding (to YZ) from the Division of Transplantation, Department of Surgery, Medical University of South Carolina and grants from: American Cancer Society Institutional Research Grant 97-219-08 (YZ), American Society of Transplant Surgeons - Team Donate Life Junior Faculty Award (MGH), NIH Grant K12RR029880 (MGH), NIH Grant R43AI073097 (subcontract to MIN), NIH Grants R01CA104947 (MIN), R01CA104947S1 (ARRA supplement to MIN), and R01DK60590 (HRR), and VA Merit Review (HRR). This manuscript was supported by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780. Its contents are the authors' sole responsibility and do not necessarily represent official NIH views. This work utilized services from the MUSC Center for Cellular Therapy for their invaluable support. The Center for Cellular Therapy is supported in part by the Clinical and Translational Science Award support grant (UL 1 RR029882) and the Hollings Cancer Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. National Centers for Disease Control and Prevention. Hepatitis C Fact Sheet,
2. World Health Organization. Hepatitis C – Global Surveillance Update. Weekly Epidemiological Record. 2000;75:17–28. [PubMed]
3. Centers for Disease Control and Prevention Web site on Hepatitis C:
4. Scientific Registry of Transplant Recipients (SRTR): OPTN/SRTR Annual report: transplant data 1993–2002. (Chapter VII). Available: www.ustransplant org. 2003.
5. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, et al. European Liver Transplant Association. Liver Transpl. 2003:1231. [PubMed]
6. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis. 2003;7:149–161. [PubMed]
7. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis. 2000;20:127–141. [PubMed]
8. Missale GR, Bertoni V, Lamonaca A, Valli M, Massari C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996;98:706–714. [PMC free article] [PubMed]
9. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, et al. Chisari. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395–1406. [PMC free article] [PubMed]
10. Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest. 2004;114:250–259. [PMC free article] [PubMed]
11. Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci. 2003;28:287–304. [PubMed]
12. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, et al. Immune evasion versus recovery following acute hepatitis c virus infection from a shared source. J Exp Med. 2005;201:1725–1731. [PMC free article] [PubMed]
13. Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 1995;55:748–52. [PubMed]
14. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA. and Nishimura M. I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163:507–513. [PubMed]
15. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein- Barr virus-encoded peptide. Clin Immunol. 2001;98:220–228. [PubMed]
16. Heemskerk HMH, Hoogeboom M, de Paus RA, Willemze R, Falkenburg JF. Redirection towards anti-leukemic reactivity of CMV specific peripheral T lymphocytes using T cell receptor gene transfer. Blood. 2002;100:218A–219A.
17. Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders W, et al. Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity. J Immunol. 2003;170:1209–1217. [PubMed]
18. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2:962–970. [PubMed]
19. Ueno TH, Tomiyama M, Fujiwara S, Takiguchi M. Functionally impaired HIV-specific CD8 T cells show high affinity TCR-ligand interactions. J Immunol. 2004;173:5451–5457. [PubMed]
20. Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, et al. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol. 2005;114:119–129. [PubMed]
21. van der Veken LT, Hoogeboom M, de Paus RA, Willemze R, Falkenburg JH, et al. HLA class II restricted T-cell receptor gene transfer generates CD4(+) T cells with helper activity as well cytotoxic capacity. Gene Ther. 2005;12:1686–95. [PubMed]
22. Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide–specific T-cell receptor genes. Blood. 2005;106:470–476. [PubMed]
23. Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, et al. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cells receptor genes. Hum Gene Ther. 2005;16:799–810. [PubMed]
24. Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, et al. Identification of a CD8-Independent Hepatitis C Virus-Specific T Cell Receptor That Does Not Require CD8 For Target Cell Recognition. Hepatology. 2006;43:973–81. [PubMed]
25. Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol. 2007;179:5845–54. [PMC free article] [PubMed]
26. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 2005;106:3062–7. [PubMed]
27. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med. 2008;14:1390–5. [PMC free article] [PubMed]
28. Dossett ML, Teague RM, Schmitt TM, Tan X, Cooper LJ, et al. Adoptive Immunotherapy of Disseminated Leukemia With TCR-transduced, CD8(+) T Cells Expressing a Known Endogenous TCR. Mol Ther. 2009;17:742–9. [PMC free article] [PubMed]
29. Duval L, Schmidt H, Kaltoft K, Fode K, Jensen JJ, Sorensen SM, et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res. 2006;12:1229–36. [PubMed]
30. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–9. [PMC free article] [PubMed]
31. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009. 2009;114:535–46. [PubMed]
32. Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, et al. Cutting Edge: Identification of Hepatitis C Virus-Specific CD8+ T Cells Restricted by Donor HLA Alleles following Liver Transplantation. J Immunol. 2004;173:5355–5359. [PubMed]
33. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745–54. [PMC free article] [PubMed]
34. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol. 2001;75:11392–400. [PMC free article] [PubMed]
35. Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, Chisari FV. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest. 1997;100:2376–85. [PMC free article] [PubMed]
36. Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc Natl Acad Sci. 1994;91:2829–2833. [PubMed]
37. Nishimura MI, Kawakami P Y, Charmley B, O'Neil J, Shilyansky JR, et al. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J Immunother. 1994;16:85–94. [PubMed]
38. Lyons GE, Roszkowski JJ, Mann S, Yee C, Kast WM, et al. TCR Tetramer Binding and the Lack There of Does Not Necessitate Antigen Reactivity in TCR Transduced T Cells. Cancer. Immunol Immunother. 2006;55:1142–50. [PubMed]
39. Lyons GE, Moore T, Brasic N, Li M, Roszkowski JJ, et al. Influence of Human CD8 on Antigen Recognition by TCR Transduced Cells. Cancer Res. 2006;66:11455–61. [PubMed]
40. Morgan RA, Dudley ME, Yu YYL, Zheng Z, et al. High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens. J Immunol. 2003;171:3287–95. [PMC free article] [PubMed]
41. Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, et al. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol. 2003;170:2582–9. [PubMed]
42. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, et al. Simultaneous Generation of CD8+ and CD4+ Melanoma Reactive T Cells By Retroviral Mediated TCR Gene Transfer. Cancer Res. 2005;65:1570–1576. [PubMed]
43. Heller KN, Gurer C, Münz C. Virus-specific CD4+ T cells: ready for direct attack. J Exp Med. 2006;203:805–8. [PMC free article] [PubMed]
44. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A. 1996;93:4102–7. [PubMed]
45. Zeh HJ, 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999;162:989–94. [PubMed]
46. Hofmann M, Radsak M, Rechtsteiner G, Wiemann K, Günder M, et al. T cell avidity determines the level of CTL activation. Eur J Immunol. 2004;34:1798–806. [PubMed]
47. Slifka MK, Whitton JL. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol. 2001;2:711–7. [PubMed]
48. Holler PD, Lim AR, Cho BK, Rund LA, Kranz DM. CD8(−) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J Exp Med. 2001;194:1043–52. [PMC free article] [PubMed]
49. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity. 2003;18:255–64. [PubMed]
50. Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, et al. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother. 2009;58:719–28. [PMC free article] [PubMed]
51. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, et al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cell in protective immunity to influenza. Immunol Rev. 2006;211:8–22. [PMC free article] [PubMed]
52. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat. 2006;13:505–14. [PubMed]
53. Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, et al. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol. 2003;171:219–25. [PubMed]
54. Heemskerk MH, Hoogeboom M, Hagedoom R, Kester MG, Willemze R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med. 2004;199:885–894. [PMC free article] [PubMed]
55. Langerman A, Callendar GG, Nishimura MI. Engineering Bifunctional T Cells as a Treatment for Immunotherapy Resistant Tumors. J Trans Med. 2004;2:42.
56. Weinhold M, Sommermeyer D, Uckert W, Blankenstein T. Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity. J Immunol. 2007;179:5534–5542. [PubMed]
57. Sobesky R, Feray C, Rimlinger F, Derian N, Dos Santos A, et al. Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. Hepatology. 2007;46:1704–1712. [PubMed]
58. Mommaas B, van Halteren AGS, Pool J, van der Veken L, Wieles B, et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica. 2005;90:1415–1421. [PubMed]
59. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Therapy. 2000;7:1063–1066. [PubMed]
60. Fujio K, Misaki Y, Setoguchi K, Morita S, Kawahata K, et al. Functional reconstitution of Class-II MHC-restricted T cell immunity mediated by retroviral transfer of the αβTCR complex. J Immunol. 2000;165:528–533. [PubMed]
61. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038–1044. [PubMed]

Articles from PLoS Pathogens are provided here courtesy of Public Library of Science